387 related articles for article (PubMed ID: 34168432)
21. Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Bhatia S; Al-Harrasi A
Drug Dev Ind Pharm; 2021 Jul; 47(7):1112-1120. PubMed ID: 34551665
[TBL] [Abstract][Full Text] [Related]
22. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound.
Wang J; Wang F; Li X; Zhou Y; Wang H; Zhang Y
Colloids Surf B Biointerfaces; 2019 May; 177():425-432. PubMed ID: 30798063
[TBL] [Abstract][Full Text] [Related]
23. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and biodistribution of paclitaxel-loaded microspheres.
Yan F; Tang S; Fu Q
Arzneimittelforschung; 2012 Apr; 62(4):176-80. PubMed ID: 22270845
[TBL] [Abstract][Full Text] [Related]
25. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
[TBL] [Abstract][Full Text] [Related]
26. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance.
Liping Y; Jian H; Zhenchao T; Yan Z; Jing Y; Yangyang Z; Jing G; Liting Q
Drug Deliv; 2022 Dec; 29(1):229-237. PubMed ID: 35001781
[TBL] [Abstract][Full Text] [Related]
27. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.
Li L; Yang M; Li R; Hu J; Yu L; Qian X
Anticancer Agents Med Chem; 2021; 21(7):910-918. PubMed ID: 32698755
[TBL] [Abstract][Full Text] [Related]
28. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles.
Calleja P; Espuelas S; Vauthier C; Ponchel G; Irache JM
J Pharm Sci; 2015 Sep; 104(9):2877-86. PubMed ID: 25600579
[TBL] [Abstract][Full Text] [Related]
29. Integrated multi-omics analysis reveals unique signatures of paclitaxel-loaded poly(lactide-co-glycolide) nanoparticles treatment of head and neck cancer cells.
Haider M; Jagal J; Bajbouj K; Sharaf BM; Sahnoon L; Okendo J; Semreen MH; Hamda M; Soares NC
Proteomics; 2023 Aug; 23(16):e2200380. PubMed ID: 37148169
[TBL] [Abstract][Full Text] [Related]
30. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin.
Cui YN; Xu QX; Davoodi P; Wang DP; Wang CH
Acta Pharmacol Sin; 2017 Jun; 38(6):943-953. PubMed ID: 28552909
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy.
Zhang Z; Lee SH; Gan CW; Feng SS
Pharm Res; 2008 Aug; 25(8):1925-35. PubMed ID: 18509603
[TBL] [Abstract][Full Text] [Related]
32. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
Gullotti E; Park J; Yeo Y
Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.
Jin C; Bai L; Wu H; Song W; Guo G; Dou K
Pharm Res; 2009 Jul; 26(7):1776-84. PubMed ID: 19384463
[TBL] [Abstract][Full Text] [Related]
34. Spermidine-mediated poly(lactic-
Tang J; Li J; Li G; Zhang H; Wang L; Li D; Ding J
Int J Nanomedicine; 2017; 12():6687-6704. PubMed ID: 28932114
[TBL] [Abstract][Full Text] [Related]
35. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.
Zhang Z; Wang X; Li B; Hou Y; Yang J; Yi L
Drug Deliv; 2018 Nov; 25(1):166-177. PubMed ID: 29299936
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
37. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system.
Baek JS; So JW; Shin SC; Cho CW
Int J Mol Med; 2012 Oct; 30(4):953-9. PubMed ID: 22859311
[TBL] [Abstract][Full Text] [Related]
38. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(ɛ-caprolactone) nanoparticles: In vitro and in vivo evaluation.
Xin H; Chen L; Gu J; Ren X; Wei Z; Luo J; Chen Y; Jiang X; Sha X; Fang X
Int J Pharm; 2010 Dec; 402(1-2):238-47. PubMed ID: 20934500
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.
Diab T; Alkafaas SS; Shalaby TI; Hessien M
Anticancer Agents Med Chem; 2020; 20(13):1582-1591. PubMed ID: 32364081
[TBL] [Abstract][Full Text] [Related]
40. Lipid-PLGA hybrid nanoparticles of paclitaxel: Preparation, characterization, in vitro and in vivo evaluation.
Godara S; Lather V; Kirthanashri SV; Awasthi R; Pandita D
Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():110576. PubMed ID: 32228957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
